BiodrugsSCIE

文章摘录

• Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial Author: Wu, Min; Li, Xiaojiao; Yang, Deming; Wang, Meng; Zhang, Hong; Li, Cuiyun; Mai, Jiajia; Yang, Lizhi; Qi, Yunpeng; Yu, Jin-Chen; Yang, Xiaolei; Wang, Zhaohe; Gu, Cailing; Ding, Yanhua Journal: BIODRUGS. 2023; Vol. 37, Issue 1, pp. 89-98. DOI: 10.1007/s40259-022-00563-5
• Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities Author: Jiang, Yuxiong; Chen, Youdong; Yu, Qian; Shi, Yuling Journal: BIODRUGS. 2023; Vol. 37, Issue 1, pp. 35-55. DOI: 10.1007/s40259-022-00569-z
• Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines Author: Ou, Bingming; Yang, Ying; Lv, Haihui; Lin, Xin; Zhang, Minyu Journal: BIODRUGS. 2023; Vol. 37, Issue 2, pp. 143-180. DOI: 10.1007/s40259-022-00575-1
• Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial Author: Li, Huiping; Huang, Yan; Chen, Zhendong; Zeng, Aiping; Zhang, Helong; Yu, Yan; Wei, Shihong; Li, Qingshan; Wang, Xiaojia; Wang, Xiangcai; Wang, Xiuwen; Yang, Runxiang; Dai, Xiumei; Bi, Minghong; Sun, Tao; Zhang, Qingyuan; Han, Cuicui; Li, Yujie; Kang, Xiaoyan; Liu, Yaxin; Zhang, Li Journal: BIODRUGS. 2023; Vol. 37, Issue 2, pp. 259-269. DOI: 10.1007/s40259-023-00579-5
• Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing Author: Shao, Taihang; Zhao, Mingye; Liang, Leyi; Tang, Wenxi Journal: BIODRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40259-023-00586-6
• Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis Author: Peng, Kuan; Blais, Joseph E.; Pratt, Nicole L.; Guo, Jeff Jianfei; Hillen, Jodie B.; Stanford, Tyman; Ward, Michael; Lai, Edward Chia-Cheng; Shin, Ju-Young; Tong, Xinning; Fan, Min; Cheng, Franco W. T.; Wu, Jing; Yeung, Winnie W. Y.; Lau, Chak-Sing; Leung, Wai Keung; Wong, Ian C. K.; Li, Xue Journal: BIODRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40259-023-00589-3
• Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus Author: Huang, Mingshu; Chen, Weixing; Wang, Min; Huang, Yisheng; Liu, Hongyu; Ming, Yue; Chen, Yuanxin; Tang, Zhengming; Jia, Bo Journal: BIODRUGS. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s40259-023-00594-6
• A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects Author: Tan Zhang, Guihong Chen, Chang Liu, Li’an Zu, Qi Wang, Yitong Wang, Jie Lv, Youzhong An, Lihou Dong, Huiyang Cheng, Shengbin Ren, Qian Wang, Qingshan Zheng, Haifeng Song, Yi Fang Journal: BIODRUGS, 2018, Vol., , DOI:10.1007/s40259-018-0326-x